A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

This study has been completed.
Sponsor:
Collaborator:
Eisai Co., Ltd.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT00853099
First received: February 27, 2009
Last updated: August 27, 2013
Last verified: August 2013
  Purpose

The purpose of this study is to assess the efficacy and safety of adalimumab in Japanese subjects with moderately to severely active ulcerative colitis (UC).


Condition Intervention Phase
Ulcerative Colitis
Biological: adalimumab
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Double-Blind, Placebo-controlled Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis.

Resource links provided by NLM:


Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Percentage of Participants With Clinical Remission at 8 Weeks [ Time Frame: Week 8 ] [ Designated as safety issue: No ]

    Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore > 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores:

    • Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal);
    • Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed);
    • Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration);
    • Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease).

    The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.


  • Percentage of Participants With Clinical Remission at 52 Weeks [ Time Frame: Week 52 ] [ Designated as safety issue: No ]

    Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore > 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores:

    • Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal);
    • Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed);
    • Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration);
    • Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease).

    The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.



Secondary Outcome Measures:
  • Percentage of Participants With Clinical Remission at 32 Weeks [ Time Frame: Week 32 ] [ Designated as safety issue: No ]

    Clinical remission was defined as a Mayo score ≤ 2 with no individual subscore > 1. The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores:

    • Stool Frequency Subscore (SFS), based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal);
    • Rectal Bleeding Subscore (RBS), based on the participant's diary and scored from zero (no blood) to three (blood only passed);
    • Endoscopy Subscore (ESS), based on colonoscopy or sigmoidoscopy and scores from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration);
    • Physician's Global Assessment (PGA) subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease).

    The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.


  • Percentage of Participants With a Clinical Response [ Time Frame: Baseline and Weeks 8, 32, and 52 ] [ Designated as safety issue: No ]

    A clinical response was defined as a decrease in Mayo score of ≥ 3 points and ≥ 30% from Baseline PLUS a decrease in the Rectal Bleeding Subscore (RBS) ≥ 1 or an absolute RBS of 0 or 1.

    The Mayo score is a composite score of ulcerative colitis disease activity calculated as the sum of four subscores:

    • Stool Frequency Subscore, based on the participant's diary and scored from zero (normal number of stools) to three (5 or more stools than normal);
    • Rectal Bleeding Subscore, based on the participant's diary and scored from zero (no blood) to three (blood only passed);
    • Endoscopy Subscore, based on colonoscopy or sigmoidoscopy and scored from zero (normal or inactive disease) to three (severe disease, spontaneous bleeding, ulceration);
    • Physician's Global Assessment subscore, based on the physician's overall assessment, and scored from zero (normal) to three (severe disease).

    The total Mayo score ranges from 0 to 12 points, with higher scores representing more severe disease.


  • Percentage of Participants With Mucosal Healing [ Time Frame: Weeks 8, 32, and 52 ] [ Designated as safety issue: No ]

    Mucosal healing was defined as an endoscopy subscore of ≤ 1 and was assessed using flexible sigmoidoscopy performed at Weeks 8, 32, and 52.

    The endoscopy subscore ranges from zero to three as follows:

    0 = Normal or inactive disease, 1 = Mild disease (erythema, decreased vascular pattern, mild friability), 2 = Moderate disease (marked erythema, absent vascular pattern, friability, erosions), 3 = Severe disease (spontaneous bleeding, ulceration).


  • Percentage of Participants With Rectal Bleeding Subscore Indicative of Mild Disease (≤ 1) [ Time Frame: Weeks 8, 32, and 52 ] [ Designated as safety issue: No ]

    Rectal bleeding was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The rectal bleeding subscore ranges from zero to three, according to the following scale:

    0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, 3 = blood alone passed.


  • Percentage of Participants With Physician's Global Assessment Subscore Indicative of Mild Disease (≤ 1) [ Time Frame: Weeks 8, 32, and 52 ] [ Designated as safety issue: No ]

    The Physician's Global Assessment Subscore acknowledges the three other subscores (Stool Frequency, Rectal Bleeding, and Endoscopy), the participant's daily record of abdominal discomfort and functional assessment, and other observations such as physical findings and the participant's performance status. Possible scores range from zero to three as follows:

    0 = Normal (other subscores are 0), 1 = Mild disease (other subscores are mostly 1), 2 = Moderate disease (other subscores are 1 to 2), 3 = Severe disease (other subscores are 2 to 3).


  • Percentage of Participants With Stool Frequency Subscore Indicative of Mild Disease (≤ 1) [ Time Frame: Weeks 8, 32, and 52 ] [ Designated as safety issue: No ]

    Stool frequency was assessed from the participant's diary, taking the worst score from the 3 days prior to each study visit. The stool frequency subscore ranges from zero to three, according to the following scale:

    0 = Normal number of stools for this participant, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal.


  • Percentage of Inflammatory Bowel Disease Questionnaire (IBDQ) Responders [ Time Frame: Baseline and Weeks 8, 32, and 52 ] [ Designated as safety issue: No ]
    An inflammatory bowel disease questionnaire responder was defined as a participant with at least a 16-point increase from Baseline in total Inflammatory Bowel Disease Questionnaire (IBDQ) score. The IBDQ is a 32-item questionnaire consisting of 4 dimensions: bowel-related symptoms, systemic function, social function, and emotional status. The responses to each question within each domain range from 1 (significant impairment) to 7 (no impairment), with the total score ranging from 32 (very poor) to 224 (perfect health-related quality of life).

  • Number of Participants With Adverse Events up to Week 8 [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.

    A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

    For more details on adverse events please see the Adverse Event section below.


  • Number of Participants With Adverse Events up to Week 52 [ Time Frame: 52 weeks ] [ Designated as safety issue: Yes ]

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    The investigator assessed the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.

    A serious adverse event is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

    For more details on adverse events please see the Adverse Event section below.



Enrollment: 274
Study Start Date: February 2009
Study Completion Date: August 2013
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo
Participants received placebo subcutaneous injections every 2 weeks for 52 weeks. From Week 8, participants with an inadequate response could switch to rescue therapy, where they initially received adalimumab 160 mg, 80 mg 2 weeks later, and then 40 mg every other week. Participants who completed the 52-week double-blind period will receive adalimumab 40 mg every other week until drug approval.
Drug: placebo
Experimental: Adalimumab 80 mg/40 mg
Participants received adalimumab 80 mg on Day 1, 40 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period will receive adalimumab 40 mg every other week until drug approval.
Biological: adalimumab
Other Names:
  • ABT-D2E7
  • Humira
Experimental: Adalimumab 160 mg/80 mg
Participants received adalimumab 160 mg on Day 1, 80 mg at Week 2 and 40 mg every other week from Week 4 to Week 50, via subcutaneous injection. From Week 8, participants with an inadequate response could switch to rescue therapy, where they received adalimumab 40 mg every other week. Participants who completed the 52-week double-blind period will receive adalimumab 40 mg every other week until drug approval.
Biological: adalimumab
Other Names:
  • ABT-D2E7
  • Humira

Detailed Description:

Patients who met all of the inclusion criteria and none of the exclusion criteria were randomized 1:1:1 to receive subcutaneous injections of adalimumab at either, 1. 160/80 mg at Week 0/2 and 40 mg every other week (eow) starting at Week 4 to Week 50, 2. 80/40 mg at Week 0/2 and 40 mg eow starting at Week 4 to Week 50, or 3. Placebo eow starting at Week 0 to Week 50 under the double-blind condition. At or after Week 8, participants who had inadequate response during the double-blind period could switch to the rescue arm, where participants from the placebo group initially received adalimumab 160 mg and 80 mg 2 weeks later and those from the adalimumab group received adalimumab 40 mg initially and 2 weeks later under double-blind conditions. All participants in the rescue arm then received 40 mg adalimumab eow until Week 50. Participants who completed the 52-week double-blind period will receive open-label adalimumab 40 mg eow starting at Week 52 and continuing until the end of the study. Participants who have an inadequate response or disease flare can dose escalate to 80 mg eow at or after Week 60. Participants who dose escalate to 80 mg eow and continue to have an inadequate response or disease flare will be withdrawn from the study

  Eligibility

Ages Eligible for Study:   15 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of ulcerative colitis for greater than 90 days prior to Baseline.
  • Active ulcerative colitis with a Mayo Score of 6-12 points at Baseline and endoscopy subscore of 2-3 during the Screening Period, despite concurrent treatment with at least one of the following (oral corticosteroids or immunosuppressants or both as defined below):
  • Stable oral corticosteroid dose (prednisolone dose of ≥ 20 mg/day or equivalent) for at least 14 days prior to Baseline or stable oral corticosteroid dose (prednisolone of 5 to less than 20 mg/day) for at least 40 days prior to Baseline. And/or
  • At least a consecutive 90-day course of azathioprine or 6-mercaptopurine (6-MP) prior to Baseline, with a dose of azathioprine ≥ 50 mg/day or 6-MP ≥ 30 mg/day, or a dose that was the highest tolerated by the patient.

Exclusion Criteria:

  • History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for ulcerative colitis or was planning bowel surgery.
  • Patients with disease limited to the rectum.
  • Indeterminate colitis and/or Crohn's disease.
  • Received any biological therapy (including infliximab) in the past.
  • History of tuberculosis or malignancy.
  • Pregnant women.
  • Patients with positive C. difficile stool assay at Screening.
  • Current diagnosis of fulminant colitis and/or toxic megacolon.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00853099

  Hide Study Locations
Locations
Japan
Site Reference ID/Investigator# 47136
Asahikawa, Japan
Site Reference ID/Investigator# 47164
Bunkyo-ku, Tokyo, Japan
Site Reference ID/Investigator# 47159
Chiba, Japan
Site Reference ID/Investigator# 47183
Chikushino, Japan
Site Reference ID/Investigator# 47222
Fukuoka, Japan
Site Reference ID/Investigator# 47135
Fukuoka, Japan
Site Reference ID/Investigator# 47124
Hamamatsu, Japan
Site Reference ID/Investigator# 47130
Hirakata, Japan
Site Reference ID/Investigator# 47103
Hirosaki, Japan
Site Reference ID/Investigator# 47131
Hiroshima, Japan
Site Reference ID/Investigator# 47178
Hiroshima, Japan
Site Reference ID/Investigator# 47179
Hiroshima, Japan
Site Reference ID/Investigator# 15853
Hokkaido, Japan
Site Reference ID/Investigator# 47176
Izumo, Japan
Site Reference ID/Investigator# 47182
Jonan-ku, Fukuoka-shi, Japan
Site Reference ID/Investigator# 47226
Kagoshima, Japan
Site Reference ID/Investigator# 47121
Kanagawa, Japan
Site Reference ID/Investigator# 47123
Kanazawa, Japan
Site Reference ID/Investigator# 47160
Kashiwa, Japan
Site Reference ID/Investigator# 47108
Kawagoe, Japan
Site Reference ID/Investigator# 47180
Kochi, Japan
Site Reference ID/Investigator# 47107
Koshigaya, Japan
Site Reference ID/Investigator# 47181
Kurume, Japan
Site Reference ID/Investigator# 47223
Kurume, Japan
Site Reference ID/Investigator# 47172
Kyoto, Japan
Site Reference ID/Investigator# 47127
Kyoto, Japan
Site Reference ID/Investigator# 47171
Kyoto, Japan
Site Reference ID/Investigator# 47170
Kyoto, Japan
Site Reference ID/Investigator# 47134
Matsuyama, Japan
Site Reference ID/Investigator# 47116
Minato, Japan
Site Reference ID/Investigator# 47147
Miyagi, Japan
Site Reference ID/Investigator# 47225
Miyazaki, Japan
Site Reference ID/Investigator# 47138
Morioka, Japan
Site Reference ID/Investigator# 47168
Nagakute, Japan
Site Reference ID/Investigator# 47125
Nagoya, Japan
Site Reference ID/Investigator# 47126
Nagoya, Japan
Site Reference ID/Investigator# 47166
Nagoya, Japan
Site Reference ID/Investigator# 47122
Niigata, Japan
Site Reference ID/Investigator# 47174
Nishinomiya, Japan
Site Reference ID/Investigator# 47224
Oita, Japan
Site Reference ID/Investigator# 47177
Okayama, Japan
Site Reference ID/Investigator# 47228
Okinawa, Japan
Site Reference ID/Investigator# 47227
Okinawa, Japan
Site Reference ID/Investigator# 47129
Osaka, Japan
Site Reference ID/Investigator# 47128
Osaka, Japan
Site Reference ID/Investigator# 47169
Otsu, Japan
Site Reference ID/Investigator# 47118
Sagamihara, Japan
Site Reference ID/Investigator# 47106
Saitama, Japan
Site Reference ID/Investigator# 47158
Saitama, Japan
Site Reference ID/Investigator# 47109
Sakura, Japan
Site Reference ID/Investigator# 47137
Sapporo, Japan
Site Reference ID/Investigator# 47104
Sendai, Japan
Site Reference ID/Investigator# 47133
Takamatsu, Japan
Site Reference ID/Investigator# 47173
Takatsuki, Japan
Site Reference ID/Investigator# 47132
Tokushima, Japan
Site Reference ID/Investigator# 47117
Tokyo, Japan
Site Reference ID/Investigator# 47111
Tokyo, Japan
Site Reference ID/Investigator# 47110
Tokyo, Japan
Site Reference ID/Investigator# 47112
Tokyo, Japan
Site Reference ID/Investigator# 47161
Tokyo, Japan
Site Reference ID/Investigator# 47165
Toyama, Japan
Site Reference ID/Investigator# 47167
Toyoake, Japan
Site Reference ID/Investigator# 47105
Yamagata, Japan
Site Reference ID/Investigator# 47175
Yamatotakada, Japan
Site Reference ID/Investigator# 47120
Yokohama, Japan
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Eisai Co., Ltd.
Investigators
Study Director: Morio Ozawa, MS AbbVie GK
  More Information

Additional Information:
No publications provided

Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier: NCT00853099     History of Changes
Other Study ID Numbers: M10-447
Study First Received: February 27, 2009
Results First Received: October 26, 2012
Last Updated: August 27, 2013
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by AbbVie:
Ulcerative Colitis

Additional relevant MeSH terms:
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Inflammatory Bowel Diseases
Pathologic Processes
Adalimumab
Antirheumatic Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on July 26, 2014